Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Uk.ResellerClub Launches New Promotion Offering Free .CO.UK Domains With Hosting Packages

LONDON, May 10, 2013 /PRNewswire/ --  Web Presence products provider Uk.ResellerClub have...

Wirecard Gains SriLankan Airlines As A New Customer In Asia

MUNICH, Germany, April 30, 2013 /PRNewswire/ -- Wirecard AG, provider of a globally accepted payment...

Global Payments Continues Focus On Mobile Payments In The UK

LONDON, March 28, 2013 /PRNewswire/ -- Global Payments is further strengthening its mobile payment...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

Results from a pivotal phase II trial of brentuximab vedotin, published in the Journal of Clinical Oncology, showed that 86% of patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL),[1] achieved the primary endpoint of objective response rate (ORR; complete remission (CR) and partial remission (PR) combined). Brentuximab vedotin is an antibody-drug conjugate directed at CD30 cell surface antigens, a defining marker of sALCL. 

The pivotal phase II trial evaluated the efficacy and safety of single-agent brentuximab vedotin in 58 patients with relapsed or refractory sALCL. Key data, included:

DURABILIT B.V., asupplier of "CO2-neutral" IT solutions and refurbished hardware, has been nominated for the Sustainable Energy Europe Awards 2012. 

The awards are an initiative started by the European Commission in 2005 and highlight the most outstanding and innovative European projects in the fields of energy efficiency and renewable energy. 

The 'Anesthesia Drugs Market (2011 - 2015) - U.S. Market Entry Study' analyzes and studies the U.S. market for intravenous anesthesia drugs with special focus on ketamine, distribution structure of anesthesia drugs in U.S., potential buyers, export&import system for controlled substances in U.S. and U.S. market entry strategy.  

ET Solar Group Corp. of China has announced completion of two ground-mounted PV power plants in Germany, with total installed capacity of over 9.6MW.

The plants are ground-mounted and are 4MW and 5.6MW by size and are located in Oberröblingen, 100 kilometers west of Leipzig, and Rätzlingen, 100 kilometers from Hamburg respectively. ET Solutions AG, ET Solar's wholly owned subsidiary, performed full engineering, procurement and construction tasks with all PV modules sourced from ET Solar's China plant.

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC). ArQule announced that this randomized, double-blind study met its primary endpoint in January and will now present the full results from this trial, including positive data in the pre-defined c-MET high population.

Additional clinical data with tivantinib will be featured in two poster discussions and two general poster sessions.